Obesity, Metabolic Syndrome Ups Risk of Recurrent Prostate Cancer
FRIDAY, Jan. 26, 2018 -- Obesity and metabolic syndrome are associated with increased recurrence among men with prostate cancer who undergo radical prostatectomy (RP), according to a study presented at the American Association for Cancer Research Special Conference -- Obesity and Cancer: Mechanisms Underlying Etiology and Outcomes -- held from Jan. 27 to 30 in Austin, Texas.
Arash Samiei, M.D., from the Allegheny Health Network in Pittsburgh, and colleagues examined the correlation of body mass index (BMI) and metabolic syndrome with oncologic outcome in a retrospective study of 1,100 prostatectomies, with a median follow-up of 44 months.
The researchers found that there were more obese patients in the high- versus low-/intermediate-risk group (41.2 versus 32.0 percent; P = 0.006). In each of the risk groups there was no statistically significant difference between surgical margin status. Higher Gleason score was seen in association with metabolic syndrome (P < 0.001) and a BMI >30 kg/m² (P = 0.028). Significantly higher biochemical recurrence was seen for patients with BMI >30 versus <30 kg/m² (32.4 versus 16.9 percent; P < 0.001). Compared to patients without metabolic syndrome, those with metabolic syndrome had increased risk of biochemical recurrence (odds ratio, 4.06; P < 0.001).
"Our study indicates that prostate cancer patients who are obese or have metabolic syndrome undergoing RP may have a higher chance for recurrence of the disease, and these individuals should have more focused follow-up care," Samiei said in a statement.
© 2020 HealthDay. All rights reserved.
Posted: January 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.